The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
Compounds that specifically inhibit the reuptake of serotonin in the brain.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
A serotonin uptake inhibitor that is effective in the treatment of depression.
A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
An activity in which the body is propelled through water by specific movement of the arms and/or the legs. Swimming as propulsion through water by the movement of limbs, tail, or fins of animals is often studied as a form of PHYSICAL EXERTION or endurance.
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
A subclass of G-protein coupled SEROTONIN receptors that couple preferentially to GI-GO G-PROTEINS resulting in decreased intracellular CYCLIC AMP levels.
The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION.
A selective serotonin uptake inhibitor that is used in the treatment of depression.
One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SEROTONIN UPTAKE INHIBITORS.
Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.
The observable response an animal makes to any situation.
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.
Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons.
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
An induced response to threatening stimuli characterized by complete loss of muscle strength.
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
The tendency to explore or investigate a novel environment. It is considered a motivation not clearly distinguishable from curiosity.
Process of preserving a dead body to protect it from decay.
A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.
A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A tricyclic antidepressant with some tranquilizing action.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.
Learned expectation that one's responses are independent of reward and, hence, do not predict or control the occurrence of rewards. Learned helplessness derives from a history, experimentally induced or naturally occurring, of having received punishment/aversive stimulation regardless of responses made. Such circumstances result in an impaired ability to learn. Used for human or animal populations. (APA, Thesaurus of Psychological Index Terms, 1994)

Block by fluoxetine of volume-regulated anion channels. (1/1011)

1. We have used the whole-cell patch clamp technique to study the effect of fluoxetine, a commonly used antidepressant drug, on the volume-regulated anion channel (VRAC) in calf pulmonary artery endothelial (CPAE) cells. We also examined its effects on other Cl- channels, i.e. the Ca2(+)-activated Cl- current (I(Cl,Ca) and the cystic fibrosis transmembrane conductance regulator (CFTR) to assess the specificity of this compound for VRAC. 2. At pH 7.4 fluoxetine induced a fast and reversible block of the volume-sensitive chloride current (I(Cl,swell)), with a Ki value of 6.0+/-0.5 microM (n = 6-9). The blocking efficiency increased with increasing extracellular pH (Ki= 0.32+/-0.01 microM at pH 8.8, n = 3-9), indicating that the blockade is mediated by the uncharged form of fluoxetine. 3. Fluoxetine inhibited Ca2(+)-activated Cl(-) currents, I(Cl,Ca), activated by loading CPAE cells via the patch pipette with 1000 nM free Ca2+ (Ki= 10.7+/-1.6 microm at pH 7.4, n=3-5). The CFTR channel, transiently transfected in CPAE cells, was also inhibited with a Ki value of 26.9+/-9.4 microM at pH 7.4 (n = 3). 4. This study describes for the first time the effects of fluoxetine on anion channels. Our data reveal a potent block of VRAC at fluoxetine concentrations close to plasma concentrations. The results suggest a hydrophobic interaction with high affinity between uncharged fluoxetine and volume-activated chloride channels. Ca(2+)-activated Cl- currents and CFTR are also blocked by fluoxetine, revealing a novel characteristic of the drug as a chloride channel modulator.  (+info)

Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. (2/1011)

AIMS: To establish the incidence, time course and risk factors of hyponatraemia complicating treatment with fluoxetine or paroxetine in an elderly population. METHODS: Retrospective descriptive and case control study in an inpatient/outpatient assessment and rehabilitation service for people aged 65 years and over. Fourteen elderly patients with hyponatraemia complicating treatment with fluoxetine or paroxetine, matched with 56 controls drawn from 845 patients treated with fluoxetine or paroxetine over 3.5 years. No other SSRI antidepressants were used over the study period. RESULTS: The incidence of hyponatraemia was 4.7/1000 people treated/year (6.3/1000 for fluoxetine and 3.5/1000 for paroxetine). Hyponatraemia was detected at a median 13.5 (mean 18.6, range 4-64) days after commencing the drug. Mean (95% confidence intervals) body weights were lower in cases at 53.0 (95% CI 46.5-59.5) kg compared with controls at 64.5 (95% CI 60.1-68.4) kg (P<0.01). 71% of cases were women compared with 45% of controls (P=0.07) but the effect of gender was confounded by body weight. There were trends for cases to be older (odds ratio 1.10: 95% CI 0.99, 1.23) and lighter (odds ratio 0.92, 95% CI 0.86, 0.99). CONCLUSIONS: Approximately 1 in 200 elderly people treated per year with fluoxetine or paroxetine developed complicating hyponatraemia. Low body weight was a particular risk factor. Most cases occurred within 3 weeks of treatment.  (+info)

Effects of fluoxetine on the polysomnogram in outpatients with major depression. (3/1011)

This study investigated the effects of open-label fluoxetine (20 mg/d) on the polysomnogram (PSG) in depressed outpatients (n = 58) who were treated for 5 weeks, after which dose escalation was available (< or = 40 mg/d), based on clinical judgment. Thirty-six patients completed all 10 weeks of acute phase treatment and responded (HRS-D < or = 10). PSG assessments were conducted and subjective sleep evaluations were gathered at baseline and at weeks 1, 5, and 10. Of the 36 subjects who completed the acute phase, 17 were reevaluated after 30 weeks on continuation phase treatment and 13 after approximately 7 weeks (range 6-8 weeks) following medication discontinuation. Acute phase treatment in responders was associated with significant increases in REM latency, Stage 1 sleep, and REM density, as well as significant decreases in sleep efficiency, total REM sleep, and Stage 2 sleep. Conversely, subjective measures of sleep indicated a steady improvement during acute phase treatment. After fluoxetine was discontinued, total REM sleep and sleep efficiency were found to be increased as compared to baseline.  (+info)

Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. (4/1011)

We characterized the effects of drugs on the uptake of [3H]neurotransmitter by and the binding of [125I](3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ([125I]RTI-55) to the recombinant human dopamine (hDAT), serotonin (hSERT), or norepinephrine (hNET) transporters stably expressed in human embryonic kidney 293 cells. RTI-55 had similar affinity for the hDAT and hSERT and lower affinity for hNET (Kd = 1. 83, 0.98, and 12.1 nM, respectively). Kinetic analysis of [125I]RTI-55 binding indicated that the dissociation rate (k-1) was significantly lower for hSERT and the association rate (k+1) was significantly lower for hNET compared with the hDAT. The potency of drugs at blocking [3H]neurotransmitter uptake was highly correlated with potency at blocking radioligand binding for hDAT and hSERT. Substrates were more potent at the inhibition of [3H]neurotransmitter uptake than radioligand binding. The potency of drugs was highly correlated between displacement of [3H]nisoxetine (Kd = 6.0 nM) and [125I]RTI-55 from the hNET, suggesting that these radioligands recognize similar sites on the transporter protein. The correlation observed between inhibitory potency for uptake and binding of either ligand at the hNET was lower than correlations between uptake and binding for hDAT and hSERT. The present results indicate that the cocaine analog [125I]RTI-55 has unique binding properties at each of the transporters and that the use of recombinant transporters expressed by a single cell type can provide a powerful screening tool for drugs interacting with biogenic amine transporters, such as possible cocaine antagonists.  (+info)

Thermogenic effects of sibutramine and its metabolites. (5/1011)

1. The thermogenic activity of the serotonin and noradrenaline reuptake inhibitor sibutramine (BTS 54524; Reductil) was investigated by measuring oxygen consumption (VO2) in rats treated with sibutramine or its two pharmacologically-active metabolites. 2. Sibutramine caused a dose-dependent rise in VO2, with a dose of 10 mg kg(-1) of sibutramine or its metabolites producing increases of up to 30% that were sustained for at least 6 h, and accompanied by significant increases (0.5-1.0 degrees C) in body temperature. 3. Based on the accumulation in vivo of radiolabelled 2-deoxy-[3H]-glucose, sibutramine had little or no effect on glucose utilization in most tissues, but caused an 18 fold increase in brown adipose tissue (BAT). 4. Combined high, non-selective doses (20 mg kg(-1)) of the beta-adrenoceptor antagonists, atenolol and ICI 118551, inhibited completely the VO2 response to sibutramine, but the response was unaffected by low, beta1-adrenoceptor-selective (atenolol) or beta2-adrenoceptor-selective (ICI 118551) doses (1 mg kg(-1)). 5. The ganglionic blocking agent, chlorisondamine (15 mg kg(-1)), inhibited completely the VO2 response to the metabolites of sibutramine, but had no effect on the thermogenic response to the beta3-adrenoceptor-selective agonist BRL 35135. 6. Similar thermogenic responses were produced by simultaneous injection of nisoxetine and fluoxetine at doses (30 mg kg(-1)) that had no effect on VO2 when injected individually. 7. It is concluded that stimulation of thermogenesis by sibutramine requires central reuptake inhibition of both serotonin and noradrenaline, resulting in increased efferent sympathetic activation of BAT thermogenesis via beta3-adrenoceptor, and that this contributes to the compound's activity as an anti-obesity agent.  (+info)

5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. (6/1011)

Serotonergic receptors of the 5-HT1A subtype have been suggested to play a pivotal role in the mechanism of action of antidepressant drugs, including specific serotonin reuptake inhibitors (SSRIs). We examined the effect of clinical doses of the SSRI, fluoxetine, on 5-HT1A receptor function in 15 normal volunteers. Hypothermic and hormone responses to the 5-HT1A receptor agonist, ipsapirone (0.3 mg per kg, per os) were examined after two weeks of placebo and again, after the subjects had been receiving fluoxetine for four weeks. On fluoxetine, the hypothermic response to ipsapirone was significantly blunted, as were ACTH, cortisol and growth hormone release. Ipsapirone plasma levels were significantly increased by fluoxetine but a pharmacokinetic effect could not have accounted for the observed blunting of 5-HT1A receptor mediated effects. These findings confirm and extend previous observations in rodents and humans and indicate that both post-synaptic 5-HT1A receptors in the hypothalamus, which mediate hormone responses to 5-HT1A agonists, and pre-synaptic 5-HT1A receptors which (putatively) mediate the hypothermic response, are rendered subsensitive by chronic SSRI administration. Since fluoxetine did not have significant effects on mood and other psychological variables in these subjects, alterations in 5-HT1A receptor function induced by SSRIs may have psychotropic relevance only in the context of existing perturbations of serotonergic function which underlie the psychopathological states in which these drugs are therapeutically effective.  (+info)

Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. (7/1011)

The most common cardiovascular side effects of antidepressants are cardiac arrhythmias and orthostatic hypotension. Little is known, however, about the mechanisms by which these adverse reactions may occur, especially with regard to newer drugs such as fluoxetine. We hypothesized that these side effects may have an electrophysiological basis at the level of the cardiac myocyte. Thus, we investigated the effects of fluoxetine and other antidepressants on action potentials and ionic currents of rat ventricular myocytes using the amphotericin B perforated patch clamp technique. Fluoxetine (10 microM) prolonged the action potential duration (APD50) to 146.7 +/- 12.9% of control value without altering resting membrane potential. Fluoxetine and sertraline potently inhibited the L-type Ca2+ current (IC50 = 2.82 and 2.31 microM, respectively), but did not significantly modify the steady-state inactivation. Amitriptyline and imipramine had similar, but slightly weaker, effects (IC50 = 3.75 and 4.05 microM, respectively). Fluoxetine attenuated the peak transient outward K+ current and also altered current kinetics, as shown by accelerated decay. Fluoxetine did not change the voltage-dependence of the steady-state inactivation. Sertraline, amitriptyline and imipramine inhibited the transient outward K+ current with potencies very similar to fluoxetine. In contrast to the other antidepressants tested, trazodone weakly inhibited the Ca2+ and K+ currents and moclobemide had no detectable effect. Our comparative pharmacology data suggest that selective serotonin reuptake inhibitors, such as fluoxetine, are as potent as tricyclic antidepressants in inhibiting L-type Ca2+ and transient outward K+ currents. These inhibitory effects may contribute to cardiovascular complications such as arrhythmias and orthostatic hypotension.  (+info)

Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. (8/1011)

1. Inhibitors of serotonin reuptake in the central nervous system, such as fluoxetine, may also affect the function of vascular tissues. Thus, we investigated the effect of fluoxetine on the vasomotor responses of isolated, pressurized arterioles of rat gracilis muscle (98 +/- 4 microns in diameter at 80 mmHg perfusion pressure). 2. We have found that increasing concentrations of fluoxetine dilated arterioles up to 155 +/- 5 microns with an EC50 of 2.5 +/- 0.5 x 10(-6) M. 3. Removal of the endothelium, application of 4-aminopyridine (4-AP, an inhibitor of aminopyridine sensitive K+ channels), or use of glibenclamide (an inhibitor of ATP-sensitive K+ channels) did not affect the vasodilator response to fluoxetine. 4. In the presence of 10(-6), 2 x 10(-6) or 10(-5) M fluoxetine noradrenaline (NA, 10(-9)-10(-5) M) and 5-hydroxytryptamine (5-HT, 10(-9)-10(-5)M)-induced constrictions were significantly attenuated resulting in concentration-dependent parallel rightward shifts of their dose-response curves (pA2 = 6.1 +/- 0.1 and 6.9 +/- 0.1, respectively). 5. Increasing concentrations of Ca2+ (10(-4) 3 x 10(-2) M) elicited arteriolar constrictions (up to approximately 30%), which were markedly reduced by 2 x 10(-6)M fluoxetine, whereas 10(-5)M fluoxetine practically abolished these responses. 6. In conclusion, fluoxetine, elicits substantial dilations of isolated skeletal muscle arterioles, a response which is not mediated by 4-AP- and ATP-sensitive K+ channels or endothelium-derived dilator factors. The findings that fluoxetine had a greater inhibitory effect on Ca2+ elicited constrictions than on responses to NA and 5-HT suggest that fluoxetine may inhibit Ca2+ channel(s) or interfere with the signal transduction by Ca2+ in the vascular smooth muscle cells.  (+info)

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance.

Fluoxetine is available under the brand name Prozac and is also available as a generic medication. It comes in various forms, including capsules, tablets, delayed-release capsules, and liquid solution. The typical starting dose for adults with depression is 20 mg per day, but the dosage may be adjusted based on individual patient needs and response to treatment.

Fluoxetine has a relatively long half-life, which means it stays in the body for an extended period of time. This can be beneficial for patients who may have difficulty remembering to take their medication daily, as they may only need to take it once or twice a week. However, it also means that it may take several weeks for the full effects of the medication to become apparent.

As with any medication, fluoxetine can cause side effects, including nausea, dry mouth, sleepiness, insomnia, dizziness, and headache. In some cases, it may also increase the risk of suicidal thoughts or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider.

Serotonin uptake inhibitors (also known as Selective Serotonin Reuptake Inhibitors or SSRIs) are a class of medications primarily used to treat depression and anxiety disorders. They work by increasing the levels of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep, among other functions.

SSRIs block the reuptake of serotonin into the presynaptic neuron, allowing more serotonin to be available in the synapse (the space between two neurons) for binding to postsynaptic receptors. This results in increased serotonergic neurotransmission and improved mood regulation.

Examples of SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro). These medications are generally well-tolerated, with side effects that may include nausea, headache, insomnia, sexual dysfunction, and increased anxiety or agitation. However, they can have serious interactions with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting an SSRI.

Second-generation antidepressants (SGAs) are a class of medications used primarily for the treatment of depression, although they are also used for other psychiatric and medical conditions. They are called "second-generation" because they were developed after the first generation of antidepressants, which include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

SGAs are also known as atypical antidepressants or novel antidepressants. They work by affecting the levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine. However, they have a different chemical structure and mechanism of action than first-generation antidepressants.

Some examples of second-generation antidepressants include:

* Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa)
* Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta)
* Norepinephrine and dopamine reuptake inhibitors (NDRIs) such as bupropion (Wellbutrin)
* Atypical antidepressants such as mirtazapine (Remeron), trazodone, and vortioxetine (Brintellix)

SGAs are generally considered to have a more favorable side effect profile than first-generation antidepressants. They are less likely to cause anticholinergic effects such as dry mouth, constipation, and blurred vision, and they are less likely to cause cardiac conduction abnormalities or orthostatic hypotension. However, SGAs may still cause side effects such as nausea, insomnia, sexual dysfunction, and weight gain.

It's important to note that the choice of antidepressant medication should be individualized based on the patient's specific symptoms, medical history, and other factors. It may take some trial and error to find the most effective and well-tolerated medication for a given patient.

Antidepressive agents are a class of medications used to treat various forms of depression and anxiety disorders. They act on neurotransmitters, the chemical messengers in the brain, to restore the balance that has been disrupted by mental illness. The most commonly prescribed types of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These medications can help alleviate symptoms such as low mood, loss of interest in activities, changes in appetite and sleep patterns, fatigue, difficulty concentrating, and thoughts of death or suicide. It is important to note that antidepressants may take several weeks to reach their full effectiveness and may cause side effects, so it is essential to work closely with a healthcare provider to find the right medication and dosage.

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter that is found primarily in the gastrointestinal (GI) tract, blood platelets, and the central nervous system (CNS) of humans and other animals. It is produced by the conversion of the amino acid tryptophan to 5-hydroxytryptophan (5-HTP), and then to serotonin.

In the CNS, serotonin plays a role in regulating mood, appetite, sleep, memory, learning, and behavior, among other functions. It also acts as a vasoconstrictor, helping to regulate blood flow and blood pressure. In the GI tract, it is involved in peristalsis, the contraction and relaxation of muscles that moves food through the digestive system.

Serotonin is synthesized and stored in serotonergic neurons, which are nerve cells that use serotonin as their primary neurotransmitter. These neurons are found throughout the brain and spinal cord, and they communicate with other neurons by releasing serotonin into the synapse, the small gap between two neurons.

Abnormal levels of serotonin have been linked to a variety of disorders, including depression, anxiety, schizophrenia, and migraines. Medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), are commonly used to treat these conditions.

Tricyclic antidepressants (TCAs) are a class of medications that were commonly used to treat depression. The name "tricyclic" comes from the chemical structure of these drugs, which contain three rings in their molecular makeup. TCAs were first developed in the 1950s and remained a popular choice for treating depression until the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s.

TCAs work by increasing the levels of neurotransmitters, such as serotonin and norepinephrine, in the brain. Neurotransmitters are chemical messengers that transmit signals between nerve cells. By increasing the levels of these neurotransmitters, TCAs can help to improve mood and alleviate symptoms of depression.

Some common examples of tricyclic antidepressants include amitriptyline, imipramine, and nortriptyline. While TCAs are effective in treating depression, they can have significant side effects, including dry mouth, blurred vision, constipation, and drowsiness. In addition, TCAs can be dangerous in overdose and may increase the risk of suicide in some individuals. As a result, they are typically used as a last resort when other treatments have failed.

Overall, tricyclic antidepressants are a class of medications that were commonly used to treat depression but have largely been replaced by newer drugs due to their side effects and potential risks.

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorders, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post-traumatic stress disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance, leading to an improvement in mood and other symptoms associated with these conditions.

Paroxetine is available under various brand names, such as Paxil and Seroxat, and it comes in different forms, including tablets, capsules, and liquid solutions. The medication is typically taken once daily, although the dosage may vary depending on the individual's needs and the specific condition being treated.

As with any medication, paroxetine can have side effects, such as nausea, dizziness, dry mouth, and sleep disturbances. In some cases, it may also cause more serious side effects, including increased risk of suicidal thoughts or behaviors in children, adolescents, and young adults, as well as an increased risk of bleeding and hyponatremia (low sodium levels).

It is important to consult with a healthcare provider before starting paroxetine or any other medication, and to follow their instructions carefully regarding dosage, timing, and potential interactions with other drugs or medical conditions.

Desipramine is a tricyclic antidepressant (TCA) that is primarily used to treat depression. It works by increasing the levels of certain neurotransmitters, such as norepinephrine and serotonin, in the brain. These neurotransmitters are important for maintaining mood, emotion, and behavior.

Desipramine is also sometimes used off-label to treat other conditions, such as anxiety disorders, chronic pain, and attention deficit hyperactivity disorder (ADHD). It is available in oral form and is typically taken one to three times a day.

Like all medications, desipramine can cause side effects, which can include dry mouth, blurred vision, constipation, dizziness, and drowsiness. More serious side effects are rare but can include heart rhythm problems, seizures, and increased suicidal thoughts or behavior in some people, particularly children and adolescents.

It is important to take desipramine exactly as prescribed by a healthcare provider and to report any bothersome or unusual symptoms promptly. Regular follow-up appointments with a healthcare provider are also recommended to monitor the effectiveness and safety of the medication.

I'm sorry for any confusion, but "swimming" is not typically considered a medical term. It refers to the act of moving through water using your arms and legs in a rhythmic pattern, often as a form of exercise, recreation, or competition. However, if you're referring to a medical condition related to swimming, such as "swimmer's ear" (otitis externa), I would be happy to provide a definition for that.

Swimmer's ear is a type of outer ear infection caused by water remaining in the ear after swimming or bathing, creating a moist environment that can lead to bacterial growth. It can also be caused by scratching or damaging the lining of the ear canal through the use of cotton swabs or other objects. Symptoms may include itching, redness, pain, and sometimes discharge from the ear. If left untreated, swimmer's ear can lead to more serious complications, such as hearing loss or damage to the inner ear.

Fluvoxamine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Fluvoxamine is primarily used to treat obsessive-compulsive disorder (OCD) and may also be prescribed for other conditions such as depression, panic disorder, or social anxiety disorder.

The medical definition of Fluvoxamine can be stated as:

Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI), is a psychotropic medication used primarily in the treatment of obsessive-compulsive disorder (OCD). It functions by increasing the availability of serotonin in the synaptic cleft, which subsequently modulates neurotransmission and helps restore emotional balance. Fluvoxamine may also be employed off-label for managing other conditions, such as depression, panic disorder, or social anxiety disorder, subject to clinical judgment and patient needs.

'Receptors, Serotonin, 5-HT1' refer to a class of serotonin receptors that are activated by the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and coupled to G proteins. These receptors play a role in regulating various physiological processes, including neurotransmission, vasoconstriction, and smooth muscle contraction. The 5-HT1 receptor family includes several subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that differ in their distribution, function, and signaling mechanisms. These receptors are important targets for the treatment of various neurological and psychiatric disorders, such as depression, anxiety, migraine, and schizophrenia.

Imipramine is a tricyclic antidepressant (TCA) medication that is primarily used to treat depression. It works by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain. Imipramine has been found to be effective in treating various types of depression, including major depressive disorder, dysthymia, and depression that is resistant to other treatments.

In addition to its antidepressant effects, imipramine is also used off-label for the treatment of several other conditions, such as anxiety disorders, attention deficit hyperactivity disorder (ADHD), enuresis (bedwetting), and chronic pain.

Imipramine was first synthesized in the 1950s and has been widely used since then. It is available in various forms, including immediate-release tablets, extended-release capsules, and liquid solutions. As with all medications, imipramine can have side effects, which may include dry mouth, blurred vision, constipation, dizziness, and sedation. In rare cases, it can cause more serious side effects, such as cardiac arrhythmias or seizures.

It is important to use imipramine under the close supervision of a healthcare provider, as dosages may need to be adjusted based on individual patient needs and responses to treatment. Additionally, imipramine should not be stopped abruptly, as doing so can lead to withdrawal symptoms or a recurrence of depression.

Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.

There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.

Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.

A serotonin receptor, specifically the 5-HT1A subtype, is a type of G protein-coupled receptor found in the central and peripheral nervous systems. These receptors are activated by the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and play important roles in regulating various physiological processes, including neurotransmission, neuronal excitability, and neuroendocrine function.

The 5-HT1A receptor is widely distributed throughout the brain and spinal cord, where it is involved in modulating mood, anxiety, cognition, memory, and pain perception. Activation of this receptor can have both inhibitory and excitatory effects on neuronal activity, depending on the location and type of neuron involved.

In addition to its role in normal physiology, the 5-HT1A receptor has been implicated in various pathological conditions, including depression, anxiety disorders, schizophrenia, and drug addiction. As a result, drugs that target this receptor have been developed for the treatment of these conditions. These drugs include selective serotonin reuptake inhibitors (SSRIs), which increase the availability of serotonin in the synaptic cleft and enhance 5-HT1A receptor activation, as well as direct agonists of the 5-HT1A receptor, such as buspirone, which is used to treat anxiety disorders.

Sertraline is a medication that belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat depression, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and in some cases, premenstrual dysphoric disorder.

Sertraline works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance, in the synaptic cleft (the space between two nerve cells where neurotransmitters are released and received). By inhibiting the reuptake of serotonin, sertraline enhances the signal strength and duration of action of this neurotransmitter, which can help alleviate symptoms associated with various mental health conditions.

It is important to note that sertraline should only be taken under the supervision of a healthcare professional, as it may have side effects and potential interactions with other medications. Always consult a medical provider for personalized advice regarding medication use.

Zimeldine is not commonly used in current medical practice due to its association with serious side effects. However, historically, it was a medication used as an antidepressant. It belongs to the class of drugs called selective serotonin reuptake inhibitors (SSRIs), which work by increasing the levels of the neurotransmitter serotonin in the brain.

Zimeldine was first synthesized in 1972 and approved for medical use in Sweden in 1982. However, it was withdrawn from the market in 1983 due to its association with a rare but serious side effect called Guillain-Barré syndrome, which is a neurological disorder that can cause muscle weakness and paralysis.

Although Zimeldine is no longer used in medical practice, it played an important role in the development of SSRIs as a class of antidepressants, which have since become widely used due to their effectiveness and relatively favorable side effect profile compared to earlier classes of antidepressants.

Serotonin plasma membrane transport proteins, also known as serotonin transporters (SERTs), are membrane-spanning proteins that play a crucial role in the regulation of serotonergic neurotransmission. They are responsible for the reuptake of serotonin (5-hydroxytryptamine or 5-HT) from the synaptic cleft back into the presynaptic neuron, thereby terminating the signal transmission and allowing for its recycling or degradation.

Structurally, SERTs belong to the family of sodium- and chloride-dependent neurotransmitter transporters and contain 12 transmembrane domains with intracellular N- and C-termini. The binding site for serotonin is located within the transmembrane domain, while the substrate-binding site is formed by residues from both the transmembrane and extracellular loops.

Serotonin transporters are important targets for various psychotropic medications, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These drugs act by blocking the SERT, increasing synaptic concentrations of serotonin, and enhancing serotonergic neurotransmission. Dysregulation of serotonin transporters has been implicated in several neurological and psychiatric disorders, such as major depressive disorder, anxiety disorders, obsessive-compulsive disorder, and substance abuse.

Amitriptyline is a type of medication known as a tricyclic antidepressant (TCA). It is primarily used to treat depression, but it also has other therapeutic uses such as managing chronic pain, migraine prevention, and treating anxiety disorders. Amitriptyline works by increasing the levels of certain neurotransmitters (chemical messengers) in the brain, such as serotonin and norepinephrine, which help to regulate mood and alleviate pain.

The medication is available in various forms, including tablets and liquid solutions, and it is typically taken orally. The dosage of amitriptyline may vary depending on the individual's age, medical condition, and response to treatment. It is essential to follow the prescribing physician's instructions carefully when taking this medication.

Common side effects of amitriptyline include drowsiness, dry mouth, blurred vision, constipation, and weight gain. In some cases, it may cause more severe side effects such as orthostatic hypotension (low blood pressure upon standing), cardiac arrhythmias, and seizures. It is crucial to inform the healthcare provider of any pre-existing medical conditions or current medications before starting amitriptyline therapy, as these factors can influence its safety and efficacy.

Amitriptyline has a well-established history in clinical practice, but it may not be suitable for everyone due to its potential side effects and drug interactions. Therefore, it is essential to consult with a healthcare professional before using this medication.

Cyclohexanols are a class of organic compounds that contain a cyclohexane ring (a six-carbon saturated ring) with a hydroxyl group (-OH) attached to it. The hydroxyl group makes these compounds alcohols, and the cyclohexane ring provides a unique structure that can adopt different conformations.

The presence of the hydroxyl group in cyclohexanols allows them to act as solvents, intermediates in chemical synthesis, and starting materials for the production of other chemicals. They are used in various industries, including pharmaceuticals, agrochemicals, and polymers.

Cyclohexanols can exist in different forms, such as cis- and trans-isomers, depending on the orientation of the hydroxyl group relative to the cyclohexane ring. The physical and chemical properties of these isomers can differ significantly due to their distinct structures and conformations.

Examples of cyclohexanols include cyclohexanol itself (C6H11OH), as well as its derivatives, such as methylcyclohexanol (C7H13OH) and phenylcyclohexanol (C12H15OH).

'Animal behavior' refers to the actions or responses of animals to various stimuli, including their interactions with the environment and other individuals. It is the study of the actions of animals, whether they are instinctual, learned, or a combination of both. Animal behavior includes communication, mating, foraging, predator avoidance, and social organization, among other things. The scientific study of animal behavior is called ethology. This field seeks to understand the evolutionary basis for behaviors as well as their physiological and psychological mechanisms.

Serotonin receptor agonists are a class of medications that bind to and activate serotonin receptors in the body, mimicking the effects of the neurotransmitter serotonin. These drugs can have various effects depending on which specific serotonin receptors they act upon. Some serotonin receptor agonists are used to treat conditions such as migraines, cluster headaches, and Parkinson's disease, while others may be used to stimulate appetite or reduce anxiety. It is important to note that some serotonin receptor agonists can have serious side effects, particularly when taken in combination with other medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs). This can lead to a condition called serotonin syndrome, which is characterized by symptoms such as agitation, confusion, rapid heart rate, high blood pressure, and muscle stiffness.

Citalopram is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram is primarily used to treat major depressive disorder and is also sometimes used to treat anxiety disorders, such as panic disorder or social anxiety disorder.

The medical definition of Citalopram can be described as follows:

Citalopram (brand name Celexa) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is primarily used to treat major depressive disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram may also be used off-label for the treatment of anxiety disorders, such as panic disorder or social anxiety disorder.

Common side effects of citalopram include nausea, dry mouth, increased sweating, sleepiness, fatigue, and insomnia. More serious side effects can include an increased risk of suicidal thoughts or behavior in children, adolescents, and young adults, as well as an increased risk of bleeding, particularly if taken with other medications that increase the risk of bleeding. Citalopram should be used with caution in patients with a history of heart disease, liver disease, or seizure disorders. It is important to follow the dosage instructions provided by your healthcare provider and to inform them of any other medications you are taking, as well as any medical conditions you have, before starting citalopram.

Serotonin antagonists are a class of drugs that block the action of serotonin, a neurotransmitter, at specific receptor sites in the brain and elsewhere in the body. They work by binding to the serotonin receptors without activating them, thereby preventing the natural serotonin from binding and transmitting signals.

Serotonin antagonists are used in the treatment of various conditions such as psychiatric disorders, migraines, and nausea and vomiting associated with cancer chemotherapy. They can have varying degrees of affinity for different types of serotonin receptors (e.g., 5-HT2A, 5-HT3, etc.), which contributes to their specific therapeutic effects and side effect profiles.

Examples of serotonin antagonists include ondansetron (used to treat nausea and vomiting), risperidone and olanzapine (used to treat psychiatric disorders), and methysergide (used to prevent migraines). It's important to note that these medications should be used under the supervision of a healthcare provider, as they can have potential risks and interactions with other drugs.

Depression is a mood disorder that is characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities. It can also cause significant changes in sleep, appetite, energy level, concentration, and behavior. Depression can interfere with daily life and normal functioning, and it can increase the risk of suicide and other mental health disorders. The exact cause of depression is not known, but it is believed to be related to a combination of genetic, biological, environmental, and psychological factors. There are several types of depression, including major depressive disorder, persistent depressive disorder, postpartum depression, and seasonal affective disorder. Treatment for depression typically involves a combination of medication and psychotherapy.

Serotonin agents are a class of drugs that work on the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) in the brain and elsewhere in the body. They include several types of medications such as:

1. Selective Serotonin Reuptake Inhibitors (SSRIs): These drugs block the reabsorption (reuptake) of serotonin into the presynaptic neuron, increasing the availability of serotonin in the synapse to interact with postsynaptic receptors. SSRIs are commonly used as antidepressants and include medications such as fluoxetine, sertraline, and citalopram.
2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): These drugs block the reabsorption of both serotonin and norepinephrine into the presynaptic neuron, increasing the availability of these neurotransmitters in the synapse. SNRIs are also used as antidepressants and include medications such as venlafaxine and duloxetine.
3. Serotonin Receptor Agonists: These drugs bind to and activate serotonin receptors, mimicking the effects of serotonin. They are used for various indications, including migraine prevention (e.g., sumatriptan) and Parkinson's disease (e.g., pramipexole).
4. Serotonin Receptor Antagonists: These drugs block serotonin receptors, preventing the effects of serotonin. They are used for various indications, including nausea and vomiting (e.g., ondansetron) and as mood stabilizers in bipolar disorder (e.g., olanzapine).
5. Serotonin Synthesis Inhibitors: These drugs block the enzymatic synthesis of serotonin, reducing its availability in the brain. They are used as antidepressants and include medications such as monoamine oxidase inhibitors (MAOIs) like phenelzine and tranylcypromine.

It's important to note that while these drugs all affect serotonin, they have different mechanisms of action and are used for various indications. It's essential to consult a healthcare professional before starting any new medication.

A depressive disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities. It can also include changes in sleep, appetite, energy levels, concentration, and self-esteem, as well as thoughts of death or suicide. Depressive disorders can vary in severity and duration, with some people experiencing mild and occasional symptoms, while others may have severe and chronic symptoms that interfere with their ability to function in daily life.

There are several types of depressive disorders, including major depressive disorder (MDD), persistent depressive disorder (PDD), and postpartum depression. MDD is characterized by symptoms that interfere significantly with a person's ability to function and last for at least two weeks, while PDD involves chronic low-grade depression that lasts for two years or more. Postpartum depression occurs in women after childbirth and can range from mild to severe.

Depressive disorders are thought to be caused by a combination of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of medication, psychotherapy (talk therapy), and lifestyle changes.

The "immobility response, tonic" is a medical term that refers to a state of decreased movement or complete immobility, often in response to stress or fear. This reaction is characterized by an increased muscle tone, which can lead to rigidity and stiffness. It's a primitive response that occurs in many animals, including humans, and is thought to be a protective mechanism that helps individuals avoid detection by predators.

In a clinical setting, the immobility response, tonic may be observed during medical procedures or situations that cause fear or discomfort. For example, some people may become immobile and rigid when they are afraid of needles or other sharp objects. This response can make it difficult to perform certain medical procedures, and healthcare providers may need to take special precautions to ensure the safety and comfort of their patients.

It's important to note that while the immobility response, tonic is a normal physiological reaction in many situations, prolonged or frequent episodes can have negative consequences on an individual's physical and mental health. Chronic stress and fear can lead to a range of health problems, including anxiety, depression, and chronic pain.

Clomipramine is a tricyclic antidepressant drug that is primarily used to treat obsessive-compulsive disorder (OCD). It works by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain. These neurotransmitters are involved in regulating mood and behavior.

Clomipramine is also used off-label to treat other conditions, including panic disorder, depression, chronic pain, and sleep disorders. It is available as a tablet or capsule and is typically taken one to three times a day. Common side effects of clomipramine include dry mouth, constipation, blurred vision, dizziness, and drowsiness.

As with all medications, clomipramine should be used under the close supervision of a healthcare provider, who can monitor its effectiveness and potential side effects. It is important to follow the dosage instructions carefully and to report any unusual symptoms or concerns to the healthcare provider promptly.

Moclobemide is a type of antidepressant known as a reversible inhibitor of monoamine oxidase A (RIMA). It works by increasing the levels of neurotransmitters (chemical messengers) in the brain, such as serotonin and noradrenaline, which helps to improve mood and alleviate symptoms of depression.

Moclobemide is specifically designed to inhibit only monoamine oxidase A, which metabolizes neurotransmitters in the brain, and not monoamine oxidase B, which is found in other parts of the body. This selectivity reduces the risk of serious side effects associated with non-selective monoamine oxidase inhibitors (MAOIs), such as hypertensive crisis caused by interactions with tyramine-rich foods or certain medications.

Moclobemide is used to treat major depressive disorders and may also be used off-label for other conditions, such as social anxiety disorder or panic disorder. It is available in various forms, including tablets and oral solution, and is typically taken two to three times a day. As with any medication, moclobemide should be taken under the supervision of a healthcare provider, who will determine the appropriate dosage and monitor for potential side effects.

Exploratory behavior refers to the actions taken by an individual to investigate and gather information about their environment. This type of behavior is often driven by curiosity and a desire to understand new or unfamiliar situations, objects, or concepts. In a medical context, exploratory behavior may refer to a patient's willingness to learn more about their health condition, try new treatments, or engage in self-care activities. It can also refer to the behaviors exhibited by young children as they explore their world and develop their cognitive and motor skills. Exploratory behavior is an important aspect of learning and development, and it can have a positive impact on overall health and well-being.

Embalming is a process used in mortuary science, where the preservation and disinfection of human remains are carried out for the purpose of delaying decomposition and preserving the appearance of the body. This procedure typically involves the removal of bodily fluids and replacement with chemical preservatives, such as formaldehyde, which help to prevent the decay of tissues.

The goal of embalming is to make it possible to view the deceased person during funerals or memorial services, allowing friends and family members an opportunity for closure and remembrance. It also enables the body to be transported over long distances without risking health hazards associated with decomposition.

There are different methods of embalming, but all share the common objective of maintaining the dignity and integrity of the deceased while providing a safe and respectful way to handle and display the body.

Maprotiline is a tetracyclic antidepressant (TCA) medication that is primarily used to treat major depressive disorder. It works by increasing the levels of neurotransmitters, such as norepinephrine and serotonin, in the brain, which can help to improve mood and alleviate symptoms of depression.

Maprotiline has a unique chemical structure that distinguishes it from other antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). It is considered to be a second-line treatment option for depression, typically reserved for use when other antidepressants have not been effective.

Like other TCAs, maprotiline can cause a range of side effects, including dry mouth, blurred vision, constipation, and dizziness. It may also cause more serious side effects, such as seizures, irregular heartbeat, and changes in blood pressure. As a result, it is important to use maprotiline under the close supervision of a healthcare provider.

Maprotiline is available in tablet form and is typically taken two to four times per day, with or without food. The dosage may be gradually increased over time to achieve the desired therapeutic effect. It may take several weeks of treatment before the full benefits of maprotiline are felt.

Fenfluramine is a drug that was previously used for the short-term treatment of obesity. It works by suppressing appetite and increasing the feeling of fullness. Fenfluramine is an amphetamine derivative and stimulates the release of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep.

Fenfluramine was commonly prescribed in combination with phentermine, another appetite suppressant, under the brand name Fen-Phen. However, in 1997, the U.S. Food and Drug Administration (FDA) issued a public health warning about the potential risk of serious heart valve damage associated with the use of fenfluramine and withdrew its approval for the drug's use. Since then, fenfluramine has not been approved for medical use in many countries, including the United States.

Mianserin is a tetracyclic antidepressant (TCA) that is primarily used to treat major depressive disorders. It functions by inhibiting the reuptake of neurotransmitters such as serotonin and noradrenaline, thereby increasing their availability in the brain and helping to alleviate symptoms of depression.

Mianserin also has additional properties, including antihistamine and anti-cholinergic effects, which can help reduce some side effects commonly associated with other antidepressants, such as insomnia and agitation. However, these same properties can also lead to side effects such as drowsiness, dry mouth, and orthostatic hypotension (a drop in blood pressure upon standing).

It's important to note that mianserin is not commonly prescribed due to its narrow therapeutic index and the risk of serious side effects, including agranulocytosis (a severe decrease in white blood cells), which can increase the risk of infection. As with any medication, it should only be taken under the close supervision of a healthcare provider.

Serotonin 5-HT1 receptor antagonists are a class of pharmaceutical drugs that block the activation of serotonin 5-HT1 receptors. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter that plays a role in various physiological functions, including mood regulation, appetite control, and sensory perception. The 5-HT1 receptor family includes several subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that are widely distributed throughout the central and peripheral nervous systems.

When serotonin binds to these receptors, it triggers a series of intracellular signaling events that can have excitatory or inhibitory effects on neuronal activity. By blocking the interaction between serotonin and 5-HT1 receptors, antagonists modulate the downstream consequences of receptor activation.

Serotonin 5-HT1 receptor antagonists are used in various clinical contexts to treat or manage a range of conditions:

1. Migraine prevention: Some 5-HT1B/1D receptor antagonists, such as sumatriptan and rizatriptan, are highly effective in aborting migraine attacks by constricting dilated cranial blood vessels and reducing the release of pro-inflammatory neuropeptides.
2. Nausea and vomiting: Certain 5-HT3 receptor antagonists, like ondansetron and granisetron, are used to prevent chemotherapy-induced nausea and vomiting by blocking the activation of emetic circuits in the brainstem.
3. Psychiatric disorders: Although not widely used, some 5-HT1A receptor antagonists have shown promise in treating depression and anxiety disorders due to their ability to modulate serotonergic neurotransmission.
4. Neuroprotection: Preclinical studies suggest that 5-HT1A receptor agonists may have neuroprotective effects in various neurological conditions, such as Parkinson's disease and stroke. However, further research is needed to establish their clinical utility.

In summary, serotonin 5-HT1 receptor antagonists are a diverse group of medications with applications in migraine prevention, nausea and vomiting management, psychiatric disorders, and potential neuroprotection. Their unique pharmacological profiles enable them to target specific pathophysiological mechanisms underlying various conditions, making them valuable tools in modern therapeutics.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Dothiepin is a tricyclic antidepressant (TCA) that was commonly used in the past to treat depression and anxiety disorders. It works by increasing the levels of certain neurotransmitters, such as serotonin and noradrenaline, in the brain. However, due to its side effects and the availability of safer and more effective antidepressants, dothiepin is not commonly prescribed anymore.

Dothiepin has a sedative effect, which can help people with depression who have trouble sleeping. It also has an analgesic effect, which can be helpful in treating chronic pain conditions. However, its use is associated with several side effects, including dry mouth, blurred vision, constipation, dizziness, and weight gain. In addition, dothiepin can cause orthostatic hypotension (a drop in blood pressure upon standing), which can increase the risk of falls and fractures in older adults.

Dothiepin is available in immediate-release and sustained-release formulations, and it is usually taken orally once or twice a day. The dosage depends on the individual's response to treatment and the severity of their symptoms. It is important to follow the doctor's instructions carefully when taking dothiepin and to report any bothersome side effects promptly.

Like other TCAs, dothiepin has a potential for overdose and can be fatal if taken in large quantities. Therefore, it should be stored in a safe place, away from children and pets. People who are taking dothiepin should inform their healthcare provider about any other medications they are taking, as well as any medical conditions they have, to avoid dangerous interactions and complications.

Sprague-Dawley rats are a strain of albino laboratory rats that are widely used in scientific research. They were first developed by researchers H.H. Sprague and R.C. Dawley in the early 20th century, and have since become one of the most commonly used rat strains in biomedical research due to their relatively large size, ease of handling, and consistent genetic background.

Sprague-Dawley rats are outbred, which means that they are genetically diverse and do not suffer from the same limitations as inbred strains, which can have reduced fertility and increased susceptibility to certain diseases. They are also characterized by their docile nature and low levels of aggression, making them easier to handle and study than some other rat strains.

These rats are used in a wide variety of research areas, including toxicology, pharmacology, nutrition, cancer, and behavioral studies. Because they are genetically diverse, Sprague-Dawley rats can be used to model a range of human diseases and conditions, making them an important tool in the development of new drugs and therapies.

Major Depressive Disorder (MDD), also simply referred to as depression, is a serious mental health condition characterized by the presence of one or more major depressive episodes. A major depressive episode is a period of at least two weeks during which an individual experiences a severely depressed mood and/or loss of interest or pleasure in nearly all activities, accompanied by at least four additional symptoms such as significant changes in appetite or weight, sleep disturbances, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, difficulty thinking, concentrating, or making decisions, and recurrent thoughts of death or suicide.

MDD can significantly impair an individual's ability to function in daily life, and it is associated with increased risks of suicide, substance abuse, and other mental health disorders. The exact cause of MDD is not fully understood, but it is believed to result from a complex interplay of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of psychotherapy (such as cognitive-behavioral therapy) and medication (such as selective serotonin reuptake inhibitors or tricyclic antidepressants).

'Learned helplessness' is a psychological concept, rather than a medical diagnosis. It was first introduced by psychologists Martin Seligman and Steven Maier in the 1960s. The term refers to a state in which an individual has learned to behave helplessly, believing they have no control over the situation or outcomes, even when opportunities for control are available.

In this state, the person may have previously experienced situations where their actions did not impact the outcome, leading them to believe that they are unable to change their circumstances. This passivity and lack of initiative can then become a persistent behavioral pattern, even in new situations where they actually could exert control and make a difference.

While 'learned helplessness' is not a medical diagnosis itself, it can contribute to the development of various mental health conditions such as depression and anxiety disorders. It is essential to recognize this state and seek professional help to address the underlying beliefs and patterns that maintain it.

Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax). Fluoxetine is ... Fluoxetine is considered a first-line medication for the treatment of impulsive aggression of low intensity. Fluoxetine reduced ... A 2009 review recommended against fluoxetine as a first-line SSRI during lactation, stating, "Fluoxetine should be viewed as a ... Meta-analysis of trials in adults conclude that fluoxetine modestly outperforms placebo. Fluoxetine may be less effective than ...
... fluoxetine and paroxetine. Fluoxetine is a racemic mixture of (R)- and (S)-fluoxetine where both enantiomers contribute to its ... Fluoxetine has the widest spectrum of activity since it is the least SERT selective of all the SSRIs. Fluoxetine also has a 5- ... Another feature of fluoxetine is a weak NE re-uptake inhibition which can have clinical effect in higher doses. Fluoxetine also ... Paroxetine is a constrained structural analogue of fluoxetine where the linear phenylpropylamine group of fluoxetine has been ...
Fluoxetine Monograph. Accessed 15 April 2021. Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer ...
Fluoxetine Treatment (2003). "Cell Proliferation in Adult Hippocampus is Decreased by Inescapable Stress: Reversal by ... For example, kainic acid-induced seizures, antidepressant (fluoxetine), neurotransmitters such as GABA and growth factors ( ... the effect of which can be reversed by treatment with fluoxetine. The largest NSC population in the brain is found in the SVZ. ... Fluoxetine Treatment". Neuropsychopharmacology. 28 (9): 1562-1571. doi:10.1038/sj.npp.1300234. PMID 12838272. Naoko Kaneko; ...
Redirects to fluoxetine. Fluonid Fluor-Op fluoresone (INN) Fluorine F-18 fluorodopa fluorodopa (18F) (INN) fluorometholone (INN ... Fluoroplex fluorouracil (INN) Fluothane fluotracen (INN) Fluotrex fluoxetine (INN) fluoxymesterone (INN) fluparoxan (INN) ...
Sloan RL, Brown KW, Pentland B (1992). "Fluoxetine as a treatment for emotional lability after brain injury". Brain Injury. 6 ( ... Brown, K. W.; Sloan, R. L.; Pentland, B. (1998). "Fluoxetine as a treatment for post-stroke emotionalism". Acta Psychiatrica ... Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K (1992). "Fluoxetine improves emotional incontinence". Brain Injury. 6 ( ... Traditionally, antidepressants such as sertraline, fluoxetine, citalopram, nortriptyline and amitriptyline have been prescribed ...
... fluoxetine (Prozac), an antidepressant; and celecoxib (Celebrex), a nonsteroidal anti-inflammatory drug. Sulfoxaflor is used as ...
In August 2004, the company prevailed in a patent case by Teva Pharmaceutical Industries related to Sarafem (Fluoxetine). On ... "Sarafem (fluoxetine hydrochloride) Tablets". Food and Drug Administration. May 19, 2006. "Warner Chilcott Completes Acquisition ...
A study of 159,810 users of either amitriptyline, fluoxetine, paroxetine or dothiepin found that the risk of suicidal behavior ... "Fluoxetine Hydrochloride Monograph for Professionals". Drugs.com. Retrieved 15 October 2019. Brent, DA (September 2016). " ... "Fluoxetine and Adult Suicidality Revisited". Journal of Clinical Psychopharmacology. 27 (6): 682-6. doi:10.1097/jcp. ...
van der Kolk, BA; Dreyfuss, D; Berkowitz, R; Saxe, G; Shera, D; Michaels, M (1994). "Fluoxetine in Post Traumatic Stress". J ...
In 1999, both Schmiegel and Molloy were inducted into the National Inventors Hall of Fame for their fluoxetine compound that ... After those testing failures, Eli Lilly succeeded in treating five mildly depressed people; fluoxetine had found its niche. Eli ... Upon testing, a member of the group, fluoxetine hydrochloride, proved to affect only the neurotransmitter serotonin. This ...
... and olanzapine/fluoxetine is more effective. Quetiapine monotherapy may be particularly helpful in psychotic depression since ... randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". The Journal ... randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". The Journal ... Amitriptyline/perphenazine Amitriptyline/haloperidol Second-generation Venlafaxine/quetiapine Olanzapine/fluoxetine Olanzapine/ ...
Fluoxetine and venlafaxine are used off-label. Fluoxetine has produced unsatisfactory mixed results. Venlafaxine showed ... Fluoxetine was developed at Eli Lilly and Company in the early 1970s by Bryan Molloy, Klaus Schmiegel, David T. Wong, and ... A study of fluoxetine-exposed pregnancies found a 12% increase in the risk of major malformations that did not reach ... Fluoxetine was approved for commercial use by the US Food and Drug Administration (FDA) in 1988, becoming the first blockbuster ...
It was also the most prescribed antidepressant (along with fluoxetine) for 12 to 17-year olds. The few randomized controlled ... Combinations of amitriptyline and fluoxetine or melatonin may reduce fibromyalgia pain better than either medication alone. ... fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder". Exp Neurol. 207 (2): 248-57. doi:10.1016 ... a moderate CYP2D6 inhibitor fluoxetine does not seem to have a significant effect on the levels of amitriptyline or ...
June 1995). "Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative ... as Eli Lilly and Company paid for a large clinical trial of fluoxetine as a potential treatment for the condition that was then ...
... take SSRIs such as fluoxetine or sertraline. Adverse drug reactions associated with fluconazole therapy include: Common (≥1% of ...
Fluoxetine is not licensed for this use. It is unclear whether SSRIs affect the risk of suicidal behavior in adults. A 2005 ... Fluoxetine, an SSRI, has also shown efficacy in animal models of graft vs. host disease. SSRIs have also been used successfully ... Fluoxetine was introduced in 1987 and was the first major SSRI to be marketed. A study examining publication of results from ... Fluoxetine is the only SSRI authorized for use in children and adolescents with moderate to severe depression in the United ...
The antidepressant fluoxetine may also be helpful. While people with schizotypal personality disorder and other attenuated ... Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY (August 1991). "Fluoxetine in the treatment of borderline and schizotypal ...
Effective antidepressants are fluoxetine, sertraline, or paroxetine. Both fluoxetine and light therapy are 67% effective in ... a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective ... a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective ... and antidepressants such as fluoxetine increase the amount of the enzyme serotonin N-acetyltransferase, resulting in an ...
As occurs with fluvoxamine, fluoxetine and phenytoin. As larger doses of these pharmaceuticals are administered the plasma ...
Further, different medicines are known to augment the activity of one another like as seen in the case of Fluoxetine which ... Andrade, Chittaranjan (1999). "Primary hypersomnia : Response to fluoxetine and methylphenidate". Indian Journal of Psychiatry ... Fluoxetine, an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class is also known to have mild stimulating ...
Balogh S, Hendricks SE, Kang J (1992). "Treatment of fluoxetine-induced anorgasmia with amantadine". The Journal of Clinical ...
Balogh S, Hendricks SE, Kang J (1992). "Treatment of fluoxetine-induced anorgasmia with amantadine". The Journal of Clinical ...
Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (April 1993). "Inhibition by fluoxetine of cytochrome P450 2D6 activity". ...
Perreault, H; Semsar, K; Godwin, J (2003). "Fluoxetine treatment decreases territorial aggression in a coral reef fish". ... Semsar, Katharine; Perreault, Heidi A.N.; Godwin, John (2004). "Fluoxetine-treated male wrasses exhibit low AVT expression". ... of AVT can induce sexual and aggressive behaviors in terminal phase male bluehead wrasses while injections of fluoxetine ( ...
In rat models this increase is also observed and can be reversed with fluoxetine with some suggestion that E site editing maybe ... Ni YG, Miledi R (March 1997). "Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)". Proceedings of the National ... Aripiprazole Agomelatine CEPC Eltoprazine Etoperidone Flibanserin Fluoxetine FR-260,010 Tedatioxetine Methysergide Mirtazapine ... but not fluoxetine, which is a 5-HT2C antagonist) indirectly stimulate 5-HT2C activity by increasing levels of serotonin in the ...
Wong, DT; Perry, KW; Bymaster, FP (2005). "Case history: The discovery of fluoxetine hydrochloride (Prozac)". Nature Reviews ... Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor ... but not by the SSRI fluoxetine. The mood changes induced by AMPT may be mediated by decreases in norepinephrine, while changes ... it is also believed that the selective NRI nisoxetine was discovered prior to the invention of fluoxetine. However, the ...
Teicher MH, Glod C, Cole JO (February 1990). "Emergence of intense suicidal preoccupation during fluoxetine treatment". The ... "Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment". Journal of the American ... were more sensitive to paradoxical reactions of self-harm and suicidal ideation while taking the antidepressant fluoxetine. ...
... fluoxetine. Nisoxetine was never marketed as a drug due to a greater interest in pursuing the development of fluoxetine, a ... The origins of nisoxetine can be found within the discovery of fluoxetine (Prozac, by Eli Lilly). In the 1970s, Bryan B. Molloy ... Reboxetine Atomoxetine Fluoxetine Kelwala S, Stanley M, Gershon S (May 1983). "History of antidepressants: successes and ... Wong DT, Perry KW, Bymaster FP (September 2005). "Case history: the discovery of fluoxetine hydrochloride (Prozac)". Nature ...
August 2004). "Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for ... Lawrence RW (August 2004). "Effect of mirtazapine versus fluoxetine on "sleep quality"". The Journal of Clinical Psychiatry. 65 ... "Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia ...
Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax). Fluoxetine is ... Fluoxetine is considered a first-line medication for the treatment of impulsive aggression of low intensity. Fluoxetine reduced ... A 2009 review recommended against fluoxetine as a first-line SSRI during lactation, stating, "Fluoxetine should be viewed as a ... Meta-analysis of trials in adults conclude that fluoxetine modestly outperforms placebo. Fluoxetine may be less effective than ...
Fluoxetine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Fluoxetine may be taken with or without food. Fluoxetine capsules, tablets, and liquid are usually taken once a day in the ... Continue to take fluoxetine even if you feel well. Do not stop taking fluoxetine without talking to your doctor. If you ... Before taking fluoxetine,. *tell your doctor and pharmacist if you are allergic to fluoxetine, any other medications, or any of ...
... capsules may be taken with or without food. If you miss a dose of fluoxetine capsules, take the missed dose as soon ... Fluoxetine Capsules, USP (floo ox e teen) Read the Medication Guide that comes with fluoxetine capsules before you start ... Store fluoxetine capsules at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). Keep fluoxetine ... Do not use fluoxetine capsules for a condition for which it was not prescribed. Do not give fluoxetine capsules to other people ...
Fluoxetine (N =1,728). Placebo (N=975). Fluoxetine (N=266). Placebo (N=89). Fluoxetine (N=450). Placebo (N=267). Fluoxetine (N= ... Do not take fluoxetine capsules if you:. *are allergic to fluoxetine hydrochloride or any of the ingredients in fluoxetine ... Enantiomers - Fluoxetine is a racemic mixture (50/50) of R-fluoxetine and S-fluoxetine enantiomers. In animal models, both ... 116 fluoxetine OCD; N=43 placebo OCD; N=14 fluoxetine bulimia; N=1 placebo bulimia; N=162 fluoxetine panic; N=121 placebo panic ...
A team of researchers from the Department of Biochemistry and Molecular Biology and the Institute of Neuroscience at the Universitat Autònoma de Barcelona has discovered that tetanus toxin, which causes tetanus, could be extremely useful as a therapy against psychological disorders such as depression, anxiety and anorexia, and to slow the progress of neurodegenerative disorders such as Parkinsons disease.. ...
Fluoxetine is used to treat depression, panic attacks, obsessive compulsive disorder, a certain eating disorder (bulimia), and ... Before taking fluoxetine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This ... Fluoxetine can stay in your body for many weeks after your last dose and may interact with many other medications. Before using ... If you are taking fluoxetine for premenstrual problems, your doctor may direct you to take it every day of the month or just ...
Quick easy-to-read overview of fluoxetine. Includes: how it works, upsides, downsides, bottom line, tips, response and ... Take fluoxetine exactly as directed by your doctor. Do not stop suddenly without your doctors advice. Fluoxetine is best ... Taking fluoxetine with other medications such as tramadol that also release serotonin or overdosing on fluoxetine may cause ... Few studies have evaluated the use of fluoxetine long-term.. *Seek medical advice if a rash develops while taking fluoxetine. ...
Fluoxetine, an antidepressant or mood elevator, is used to treat depression and anxiety. It also has been used to treat obesity ... Fluoxetine Description. Generic Name : FLUOXETINE. Pronunciation : (floo ox e teen). Trade Name(s) : Dawnex, Fludac, Flufran, ... 3. Do not stop taking fluoxetine without consulting your doctor. 4. Fluoxetine can cause dizziness and drowsiness. Do not drive ... 1. Fluoxetine is usually taken once a day, in the morning, or twice a day, in the morning and at noon. 2. Follow the ...
Buy Fluoxetine 40 mg (sold per capsule) and other Anxiety from top brands at 1800PetMeds and save. Free shipping on orders over ...
FLUOXETINE (floo OX e teen) treats premenstrual dysphoric disorder (PMDD). It increases the amount of serotonin in the brain, a ... An unusual or allergic reaction to fluoxetine, other medications, foods, dyes, or preservatives ...
Capsules; Oral; Fluoxetine Hydrochloride 20 mg*Liquid; Oral; Fluoxetine Hydrochloride 20 mg / 5 ml*Tablets; Oral; Fluoxetine ...
Bioaccumulation. Fluoxetine has low potential for bioaccumulation.. Toxicity. Fluoxetine has very high chronic toxicity.. Risk ... Fluoxetine is recommended in the Wise list primarily for children and adolescents in depression. Fluoxetine is recommended in ... Fluoxetine is not recommended for the elderly.. *Avoid randomized prescribing of SSRIs (e.g., fluoxetine). Evaluate and ... Fluoxetine slowly disappears from water sediment systems. [---] The degradation phrase Fluoxetine is potentially persistent ...
fluoxetine hydrocholoride: a selective-serotonin reuptake inhibitor commonly prescribed as an antidepressant (trade names ... Help support Wordnik (and make this page ad-free) by adopting the word fluoxetine hydrocholoride. ...
Fluoxetine is also used to reduce or eliminate the symptoms of obsessive-compulsive disorder (OCD) as well as to treat the ... Fluoxetine belongs to a class of medications called selective serotonin reuptake inhibitors (SSRIs). It is used for the ... 02225174 PHL-FLUOXETINE - SOLUTION 20MG/5ML. 02223503 PHL-FLUOXETINE - CAP 20MG. 02223481 PHL-FLUOXETINE - CAP 10MG. ... Bleeding: Fluoxetine may cause a reduced number of platelets in the blood, which can make it difficult to stop cuts from ...
Similar words for Fluoxetine. Definition: noun. a selective-serotonin reuptake inhibitor commonly prescribed as an ... Sentences with fluoxetine 1. Noun, singular or mass Vets prescribe fluoxetine and sertraline for a number of anxiety-related ... Arginine did not block the antidepressant effects of Prozac, generically fluoxetine, and Wellbutrin, or bupropion. 3. Verb, ... 1. fluoxetine noun. a selective-serotonin reuptake inhibitor commonly prescribed as an antidepressant (trade names Prozac or ...
Fluoxetine. Antidepressants. Sertraline and sex. Sertraline and OCD. Long-term sertraline. Sertraline v mirtazapine. Sertraline ... Fluoxetine and sertraline dosages in major depression by. Cantrell R, Gillespie W, Altshuler L. Department of Psychiatry, UCLA ... Eighty-one percent of the fluoxetine responders compared to 32% of sertraline responders were at the manufacturers recommended ... No significant differences were found in overall response rates between the fluoxetine (81% responders) and sertraline (76% ...
2011) Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 6:e16646, doi: ... lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine ... 2005) How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 25:648-651, doi:10.1523/JNEUROSCI. ... Fluoxetine Exposure during Adolescence Alters Responses to Aversive Stimuli in Adulthood Message Subject (Your Name) has ...
Fluoxetine 10 mg, 100 Capsules are indicated for the treatment of canine separation anxiety in conjunction with a behavior ... VetDepot offers Fluoxetine 20 mg, 100 Capsules at the most competitive prices. Get the best deals on all your pet meds at ... Fluoxetine HCIs main ingredient is fluoxetine hydrochloride which is a selective serotonin reuptake inhibitor, or SSRI. * ... "prodUrl":"/fluoxetine-10-mg-30-tablets.html",. "vars":. [. {"varInfo":["tablets","30"]}. ,. {"varInfo":["mg","10"]}. ]. },. {. ...
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more ... Fluoxetine (Prozac). Subscribe to New Research on Fluoxetine The first highly specific serotonin uptake inhibitor. It is used ... 11/01/1993 - "Recent reports suggest that fluoxetine in doses less than the standard 20 mg/day may be effective in the ... 04/18/2002 - "By contrast, in only one placebo-controlled study fluoxetine (SSRI) has shown to be effective in the treatment of ...
Fluoxetine is an antidepressant that helps with obsessive compulsive behaviors such as tail chasing in dogs, or constant ... Fluoxetine is an antidepressant belonging to a group of drugs called selective serotonin reuptake inhibitors (SSRI). ... If these or any other side effects occur, stop giving your pet Fluoxetine and contact your veterinarian. ...
Free coupons for fluoxetine (prozac). Discounts up to 80% off the retail price. ... Compare Fluoxetine (prozac) 20 mg prices from verified online pharmacies or local U.S. pharmacies. ... Fluoxetine Prices - (Prozac) Compare Fluoxetine (Prozac) prices available at Canadian and international online pharmacies with ... Sign up for Fluoxetine Price Alerts. PharmacyChecker provides free monthly email updates of the latest prices. ...
ACCEL FLUOXETINE, 20MG, CAPSULE. Common uses. This medication is typically used for depression. It may also be used for bulimia ...
... Nov 5, 2019. Kenny Walter ... The investigators found that the fluoxetine group had a mean score of 9.02 points, while the placebo group had a mean score of ... "The mean CYBOCS-PDD score from baseline to 16 weeks decreased in the fluoxetine group from 12.80 to 9.02 points (3.72-point ... The participants were randomized to either receive fluoxetine (n=75) or placebo (n=71). The medication group received either 4 ...
These data demonstrate the differential effects of mirtazapine and fluoxetine, with significant improvement in favor of ... Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia J ... This study compares the effects of mirtazapine and fluoxetine on sleep continuity measures in DSM-IV MDD patients with insomnia ... Subjects were randomly assigned to either fluoxetine (20-40 mg/day) or mirtazapine (15-45 mg/day) treatment for an 8-week, ...
Check out buy-fluoxetine-40-mg-anr recipes and cookbooks on BakeSpace. You can also create your own online kitchen, swap ... Buy Fluoxetine 40 Mg 2022. 0 minutes ago, Buy Fluoxetine 40 Mg Online from TRUST STORE! Generic Buy Fluoxetine 40 Mg Without ...
fluoxetine 20 mg acheter fluoxetine generique fluoxetine. fluoxetine 20 mg fluoxetine poux. fluoxetine 20 mg fluoxetine la ... achat fluoxetine en ligne fluoxetine 20 mg achat. acheter fluoxetine achat fluoxetine. achat fluoxetine en ligne fluoxetine ... acheter fluoxetine fluoxetine achat. fluoxetine acheter en ligne fluoxetine 20 mg achat. fluoxetine achat en ligne fluoxetine ... fluoxetine 20 mg pharmacie fluoxetine sans ordonnance. fluoxetine 20 mg vente fluoxetine. fluoxetine 20 mg acheter vrai ...
Prozac for your pets? Fluoxetine treats pets with mental illnesses and behaviors and improves their mood with a happy chemical ... What do the Fluoxetine reviews say? Fluoxetine reviews rate 5 out of 5 stars. Most reviewers say that Fluoxetine, as the ... Fluoxetine for dogs? Behavioral issues and Fluoxetine therapies may be used differently between cats and dogs. Fluoxetine for ... How Long Does It Take for Fluoxetine to Work in Cats?. Answer The medicine Fluoxetine has the main ingredient as Fluoxetine ...
Fluoxetine is a generic form of PROZac and is an SSRI antidepressant. It affects chemicals in the brain that may be unbalanced ... Fluoxetine is a generic form of PROZac and is an SSRI antidepressant. It affects chemicals in the brain that may be unbalanced ... Home/Pharmaceuticals » Prescription/Antidepressants, Anticonvulsants & Anti-Anxiety/RX FLUOXETINE HCL 10MG,30 TABLETS ... product/fluoxetine-tablets-10mg-30-tablets/Pharmaceuticals-Prescription-Antidepressants-Anticonvulsants-Anti-Anxiety/ ...
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years ... Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac): Y.G. Ni & R. Miledi; Proc. Natl. Acad. Sci. USA 94, 2036 (1997), ... Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine: P. Fan, et al.; Neuroscience 62, 515 (1994), ...

No FAQ available that match "fluoxetine"

No images available that match "fluoxetine"